



## **SciGen Partners with Sandoz for Commercialization of Human Growth Hormone**

**11<sup>th</sup> September 2007:** Scigen Limited (ASX:SIE) announces a partnership with Sandoz GmbH of Austria, a wholly owned subsidiary of Novartis, to commercialize a recombinant Human Growth Hormone throughout the Asia Pacific region including Australia. Sandoz will supply Scigen with product manufactured in its state of the art Biotechnology manufacturing facility in Austria and SciGen will lend its expertise gained both in the development and commercialization of rhuman Growth Hormone. SciGen will continue to be a serious player in a franchise that it has developed over the past 18 years and have demonstrated significant increases in human Growth Hormone revenues year after year.

Sandoz rhuman Growth Hormone, which is both lyophilized and a ready to inject product has gained approval with the EMEA in Europe, the FDA in the USA and the TGA in Australia. Other countries will soon follow.

SciGen will have the availability of its needle-free device SciTojet™ and a pen device for the ready to inject product.

### **About Human Growth Hormone:**

Human Growth Hormone is used for the treatment of short stature due to growth hormone deficiency in children, the chromosomal abnormality Turner syndrome in which females lack one of the two X chromosomes, chronic kidney problems, muscle wasting in AIDS and other conditions and growth hormone deficiency in adults. Growth hormone deficiency, either a total or a partial condition, results in impaired physical development.

Growth hormone is one of the hormones produced in the pituitary, a small gland on the underside of the brain. The pituitary is under the hormonal control of another region of the brain. Growth hormone released into the bloodstream reaches the liver where it acts to stimulate the secretion of insulin-like growth factor (IGF-1).

### **About SciTojet™:**

SciTojet™ is a needle-free injection device manufactured by Antares Pharma of the USA to which SciGen has the non-exclusive commercial rights for the Asia-Pacific region. The SciTojet2™ releases an ultra-fine stream of product under pressure which is able to penetrate the skin and deposit the medication close to blood vessels for distribution to the body. Compared to needles on syringes, the device aids in self-administration by patients and leads to better compliance with therapy, especially for children.



### **About SciGen:**

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands

### **Further information:**

| Company – Investor Relations                                                                | Company                                                                                              |
|---------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Ms. Maria Aroyan<br>SciGen Australia<br>+61 2 9485 1800<br>email: mariaaroyan@scigen.com.au | Saul Mashaal<br>Chairman, Founder & CEO<br>SciGen Ltd.<br>+ 61 2 9485 1800<br>+65 9630 5691 (Mobile) |